JP2017515847A - がんの治療のための腫瘍溶解性ウイルスおよびオーロラキナーゼ阻害薬 - Google Patents

がんの治療のための腫瘍溶解性ウイルスおよびオーロラキナーゼ阻害薬 Download PDF

Info

Publication number
JP2017515847A
JP2017515847A JP2016567517A JP2016567517A JP2017515847A JP 2017515847 A JP2017515847 A JP 2017515847A JP 2016567517 A JP2016567517 A JP 2016567517A JP 2016567517 A JP2016567517 A JP 2016567517A JP 2017515847 A JP2017515847 A JP 2017515847A
Authority
JP
Japan
Prior art keywords
oncolytic
virus
hsv1716
aurora
mln8237
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016567517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515847A5 (https=
Inventor
コナー，ジョー
Original Assignee
ウイルツ・バイオロジクス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウイルツ・バイオロジクス・リミテッド filed Critical ウイルツ・バイオロジクス・リミテッド
Publication of JP2017515847A publication Critical patent/JP2017515847A/ja
Publication of JP2017515847A5 publication Critical patent/JP2017515847A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016567517A 2014-05-12 2015-05-07 がんの治療のための腫瘍溶解性ウイルスおよびオーロラキナーゼ阻害薬 Pending JP2017515847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1408297.8A GB201408297D0 (en) 2014-05-12 2014-05-12 Treatment of cancer
GB1408297.8 2014-05-12
PCT/GB2015/051347 WO2015173544A1 (en) 2014-05-12 2015-05-07 Oncolytic virus and aurora kinase inhibitor for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2017515847A true JP2017515847A (ja) 2017-06-15
JP2017515847A5 JP2017515847A5 (https=) 2018-06-14

Family

ID=51032548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567517A Pending JP2017515847A (ja) 2014-05-12 2015-05-07 がんの治療のための腫瘍溶解性ウイルスおよびオーロラキナーゼ阻害薬

Country Status (6)

Country Link
US (1) US20170071991A1 (https=)
EP (1) EP3142677A1 (https=)
JP (1) JP2017515847A (https=)
CN (1) CN106535940A (https=)
GB (1) GB201408297D0 (https=)
WO (1) WO2015173544A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085890A1 (en) * 2016-07-29 2020-03-19 Ohio State Innovation Foundation Expression of pten-long with ocolytic viruses
US11357776B2 (en) 2016-10-28 2022-06-14 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
CN110869052A (zh) * 2016-12-23 2020-03-06 维图生物制剂公司 癌症的治疗
CN109576231B (zh) 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
CN109985239B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 极光激酶抑制剂和甲病毒在制备抗肿瘤药物的应用
CN116004567A (zh) * 2022-12-07 2023-04-25 北京大学 极光激酶b基因k202突变及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135641A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6309274B2 (ja) * 2011-03-11 2018-04-11 ターンストーン・リミテッド・パートナーシップ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
US9056133B2 (en) * 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135641A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALLEN CORY; IANKOV IANKO; OPYRCHAL MATEUSZ; ET AL: "THE AURORA A KINASE INHIBITOR MLN8237 SIGNIFICANTLY ENHANCES THE ANTITUMOR ACTIVITY OF 以下備考", MOLECULAR THERAPY, vol. VOL:20, NR:SUPPL.1, JPN5017004032, 19 May 2012 (2012-05-19), US, pages 166, ISSN: 0004182333 *
BRAIN AND NERVE, 2009, VOL.61 NO.7 PAGE.815-822, JPN6019017949, ISSN: 0004182335 *
LIBERTINI S; ABAGNALE A; PASSARO C; BOTTA G; ET AL: "AZD1152 NEGATIVELY AFFECTS THE GROWTH OF ANAPLASTIC THYROID CARCINOMA CELLS AND ENHANCES 以下備考", ENDOCRINE RELATED CANCER, vol. VOL:18, NR:1, JPN5017004031, 11 November 2010 (2010-11-11), pages 129 - 141, ISSN: 0004182332 *
QUIGG M; MAIRS R J; BROWN S M; HARLAND J; ET AL: "ASSESSMENT IN VITRO OF A NOVEL THERAPEUTIC STRATEGY FOR GLIOMA, COMBINING HERPES SIMPLEX 以下備考", MEDICINAL CHEMISTRY, vol. VOL:1, NR:5, JPN5017004034, September 2005 (2005-09-01), pages 423 - 429, ISSN: 0004037488 *
TOYOIZUMI T; ET AL: "COMBINES THERAPY WITH CHEMOTHERAPEUTIC AGENTS AND HERPES SIMPLEX VIRUS TYPE 1 ICP34.5 以下備考", HUMAN GENE THERAPY, vol. 10, JPN5017004033, 10 December 1999 (1999-12-10), US, pages 3013 - 3029, ISSN: 0004182334 *

Also Published As

Publication number Publication date
EP3142677A1 (en) 2017-03-22
WO2015173544A1 (en) 2015-11-19
CN106535940A (zh) 2017-03-22
US20170071991A1 (en) 2017-03-16
GB201408297D0 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
JP2017515847A (ja) がんの治療のための腫瘍溶解性ウイルスおよびオーロラキナーゼ阻害薬
Saha et al. Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models
Cheng et al. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr‐mediated PD‐L1 axis in epidermal growth factor receptor‐positive cancers
KR20190008913A (ko) Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법
WO2020024976A1 (en) Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
Luzzi et al. Targeting the medulloblastoma: A molecular-based approach
CN114224889B (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
BR112019026795A2 (pt) uso do anticorpo anti cd70 argx-110 para tratamento da leucemia mieloide aguda
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
MX2014010164A (es) Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
Carlo-Stella et al. A first-in-human study of tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in patients with relapsed/refractory hematologic malignancies: results from the European study
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
Montero et al. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
US20200000861A1 (en) Treatment of cancer
Rothkamm et al. Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays
Goulart et al. A phase I/II trial of ruxolitinib with chemotherapy for patients with relapsed and/or refractory Philadelphia-like acute lymphoblastic leukemia
Odhiambo et al. Preclinical evaluation of the ATR inhibitor BAY 1895344 as a radiosensitizer for head and neck squamous cell carcinoma
US20210212997A1 (en) Methods of enhancing immunity
US20140056910A1 (en) Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug
Danciulescu et al. Temozolomide and targeted therapy against epidermal growth factor receptor in glioma
TWI646974B (zh) 組合療法
KR102230514B1 (ko) 글리아딘 펩타이드를 사용한 암 치료용 키트 및 방법
US20230365673A1 (en) Means for reducing radio- and chemotherapy resistance and adverse effects
US20240277792A1 (en) Oncolytic viruses and methods of use thereof for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190521

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191224